Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
EGPA - Eosinophilic Granulomatosis With Polyangiitis
Interventions
DRUG

Tezepelumab

Tezepelumab subcutaneous injection

DRUG

Placebo

Placebo subcutaneous injection

Trial Locations (13)

AB25 2ZN

Aberdeen Royal Infirmary - NHS Grampian, Aberdeen

B15 2GW

University Hospitals Birmingham NHS Foundation Trust, Birmingham

CB2 0QQ

Cambridge University Hospitals NHS Foundation Trust, Cambridge

LE3 9QP

University Hospitals of Leicester NHS Trust, Leicester

L7 8YE

Liverpool University Hospitals NHS Foundation Trust, Liverpool

EC1A 7BE

Barts Health NHS Trust, London

NW3 2QG

Royal Free London NHS Trust, London

SE1 9RT

Guy's Hospital - Guy's and St Thomas' NHS Foundation Trust, London

SW3 6NP

Royal Brompton Hospital - Guy's and St Thomas' NHS Foundation Trust, London

W2 1PG

Imperial College Healthcare NHS Trust, London

M13 9WL

Manchester University NHS Foundation Trust, Manchester

NG7 2UH

Nottingham University Hospitals NHS Foundation Trust, Nottingham

SO16 6YD

University Hospital Southampton NHS Foundation Trust, Southampton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Imperial College London

OTHER